Is Vandetanib useful in non-small cell lung cancer?

Vandetanib (Vandetanib) is a once-daily oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. A phase II evaluation of vandetanib in patients with advanced refractory non-small cell lung cancer showed that it was effective in some non-small cell lung cancer. It has a dual effect in lung cancer cells. Both monotherapy (versus gefitinib) and combined treatment with docetaxel (versus docetaxel alone) can improve progression-free survival. Vandetanib induces autophagy by increasing the level of reactive oxygen species (ROS) in Calu-6 cells, and the blockade of autophagy or ROS effectively enhances the cell death effect of vandetanib.